A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Our Strategy Our objective is to develop and commercialize our product candidates to treat diseases where the innate immune system is dysfunctional causing or contributing to the patient’s disease. Innate immune dysfunction can occur for a variety of reasons including genetics, lifestyle, and other factors. However, age plays a significant role in the development of immune dysfunction. Innate immune dysfunction can be seen in cancer where Natural Killer (“NK”) cells are impaired and facilitate a tumor’s evasion of the immune system and subsequent disease progression. Chronic inflammation is implicated in neurologic and metabolic diseases where it impairs the innate immune system. Our initial focus continue to be treatment of cancer with INKmune and Alzheimer’s Disease (“AD”) and Treatment Resistant Depression (“TRD”) with XPro1595.
| Metric | TTM | FY2023 |
|---|---|---|
| Revenue | 0 | - |
| Net Income | -53M | -30M |
| EPS | $-3.39 | $-1.66 |
| Free Cash Flow | 0 | -12M |
| ROIC | -128.3% | -63.5% |
| Gross Margin | - | - |
| Debt/Equity | 0.00 | 0.53 |
| Dividends/Share | $0.00 | - |
| Operating Income | -54M | -30M |
| Operating Margin | 0.0% | - |
| ROE | -207.9% | -61.6% |
| Shares Outstanding | 27M | 18M |
| Metric | ||
|---|---|---|
| Income Statement | ||
| Revenue | N/A | 0 |
| Gross Margin | N/A | N/A |
| R&D | N/A | N/A |
| SG&A | N/A | N/A |
| EBIT | -30M | -54M |
| Op. Margin | N/A | 0.0% |
| Net Income | -30M | -53M |
| Net Margin | N/A | 0.0% |
| Non-Recurring | 0 | 0 |
| Returns on Capital | ||
| ROIC | -63.5% | -128.3% |
| ROE | -61.6% | -207.9% |
| ROA | -43.2% | -158.2% |
| Cash Flow | ||
| Op. Cash Flow | -12M | -27M |
| Free Cash Flow | -12M | 0 |
| Owner Earnings | -19M | -34M |
| CapEx | 0 | 0 |
| Maint. CapEx | 0 | 0 |
| Growth CapEx | N/A | 0 |
| D&A | 0 | 0 |
| CapEx/OCF | N/A | 0.0% |
| Capital Allocation | ||
| Dividends Paid | 0 | 0 |
| Dividend Yield | N/A | N/A |
| Share Buybacks | 0 | 0 |
| Buyback Yield | N/A | 0.0% |
| Stock-Based Comp | 7.4M | 7.4M |
| Debt Repayment | 5.0M | 5.0M |
| Balance Sheet | ||
| Net Debt | -16M | -28M |
| Cash & Equiv. | N/A | 28M |
| Long-Term Debt | 9.9M | 9.9M |
| Debt/Equity | 0.53 | 0.00 |
| Interest Coverage | -16.7 | -16.7 |
| Equity | 37M | 25M |
| Total Assets | 57M | 33M |
| Total Liabilities | 19M | 8.0M |
| Intangibles | 33M | 33M |
| Retained Earnings | -121M | -121M |
| Working Capital | 21M | 21M |
| Current Assets | 40M | 40M |
| Current Liabilities | 18M | 18M |
| Per Share Data | ||
| EPS | -1.66 | -3.39 |
| Owner EPS | -1.07 | -1.28 |
| Book Value | 2.07 | 0.95 |
| Cash Flow/Share | -0.66 | -1.98 |
| Dividends/Share | N/A | 0.00 |
| Shares Out. | 18.0M | 26.6M |
| Valuation | ||
| P/E Ratio | N/A | -0.4 |
| P/FCF | N/A | N/A |
| EV/EBIT | N/A | N/A |
| Price/Book | 5.5 | 1.3 |
| Price/Sales | N/A | N/A |
| FCF Yield | -5.8% | N/A |
| Market Cap | 206M | 33M |
| Avg. Price | 8.16 | 1.26 |
| Year-End Price | 11.45 | 1.26 |
Inmune Bio, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Inmune Bio, Inc. (INMB) has a 5-year average return on invested capital (ROIC) of -63.5%. This is below average and may indicate limited pricing power.
Inmune Bio, Inc. (INMB) has a market capitalization of $33M. It is classified as a small-cap stock.
Inmune Bio, Inc. (INMB) does not currently pay a regular dividend.
Inmune Bio, Inc. (INMB) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
Inmune Bio, Inc. (INMB) generated $-12 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Inmune Bio, Inc. (INMB) has a debt-to-equity ratio of 0.53. This indicates moderate leverage.
Inmune Bio, Inc. (INMB) reported earnings per share (EPS) of $-1.66 in its most recent fiscal year.
Inmune Bio, Inc. (INMB) has a return on equity (ROE) of -61.6%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 1 years of financial data for Inmune Bio, Inc. (INMB), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Inmune Bio, Inc. (INMB) has a book value per share of $2.07, based on its most recent annual SEC filing.